| Primary |
| Drug Use For Unknown Indication |
38.1% |
| Unevaluable Event |
24.6% |
| Product Used For Unknown Indication |
4.5% |
| Urinary Tract Infection |
4.5% |
| Lung Disorder |
4.2% |
| Osteitis |
3.4% |
| Prostatitis |
2.0% |
| Respiratory Tract Infection |
2.0% |
| Pneumonia Necrotising |
1.9% |
| Pyelonephritis Acute |
1.8% |
| Pyrexia |
1.7% |
| Hypertension |
1.6% |
| Bronchitis |
1.5% |
| Sepsis |
1.5% |
| Febrile Bone Marrow Aplasia |
1.3% |
| Hiv Infection |
1.3% |
| Pneumonia |
1.3% |
| Acute Myeloid Leukaemia |
1.1% |
| Erysipelas |
1.0% |
| Bile Duct Stone |
0.9% |
|
| Renal Failure Acute |
14.9% |
| Thrombocytopenia |
12.1% |
| Toxic Skin Eruption |
12.1% |
| Vascular Purpura |
7.1% |
| International Normalised Ratio Increased |
5.7% |
| Neutropenia |
5.0% |
| Skin Exfoliation |
5.0% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
4.3% |
| Stevens-johnson Syndrome |
4.3% |
| Status Epilepticus |
3.5% |
| Pancytopenia |
2.8% |
| Rash Maculo-papular |
2.8% |
| Subcutaneous Haematoma |
2.8% |
| Subdural Haematoma |
2.8% |
| Tendon Disorder |
2.8% |
| Toxic Epidermal Necrolysis |
2.8% |
| Weight Decreased |
2.8% |
| Acute Generalised Exanthematous Pustulosis |
2.1% |
| Arthralgia |
2.1% |
| Hallucination |
2.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
23.9% |
| Product Used For Unknown Indication |
18.1% |
| Pneumonia |
7.5% |
| Lung Disorder |
5.8% |
| Infection |
4.1% |
| Osteitis |
3.9% |
| Hypertension |
3.3% |
| Urinary Tract Infection |
3.3% |
| Pyrexia |
3.2% |
| Unevaluable Event |
3.0% |
| Dermo-hypodermitis |
2.9% |
| Antibiotic Therapy |
2.8% |
| Enterococcal Infection |
2.8% |
| Escherichia Infection |
2.8% |
| Respiratory Tract Infection Bacterial |
2.8% |
| Acute Myeloid Leukaemia |
2.5% |
| Pneumonia Necrotising |
2.0% |
| Prostatitis |
2.0% |
| Crohn's Disease |
1.7% |
| Prophylaxis |
1.6% |
|
| Toxic Skin Eruption |
15.0% |
| Renal Failure Acute |
9.8% |
| Thrombocytopenia |
7.5% |
| Toxic Epidermal Necrolysis |
7.0% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
6.1% |
| Skin Exfoliation |
6.1% |
| Vascular Purpura |
5.6% |
| Renal Failure |
4.7% |
| Pyrexia |
4.2% |
| Stevens-johnson Syndrome |
4.2% |
| Vomiting |
4.2% |
| Transaminases Increased |
3.7% |
| Neutropenia |
3.3% |
| Weight Decreased |
3.3% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.8% |
| Rash |
2.8% |
| Rash Morbilliform |
2.8% |
| Cholangitis |
2.3% |
| Hypotension |
2.3% |
| Jaundice Cholestatic |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
32.6% |
| Drug Use For Unknown Indication |
30.7% |
| Pyelonephritis |
3.6% |
| Hiv Infection |
3.1% |
| Infection |
2.9% |
| Hypertension |
2.5% |
| Hyperthermia |
2.5% |
| Septic Shock |
2.5% |
| Sepsis |
2.0% |
| Prophylaxis |
1.9% |
| B-cell Lymphoma |
1.8% |
| Breast Cancer |
1.8% |
| Pyrexia |
1.8% |
| Urinary Tract Infection |
1.8% |
| Anxiety |
1.6% |
| Multiple Myeloma |
1.6% |
| Antibiotic Therapy |
1.4% |
| Acute Myeloid Leukaemia |
1.3% |
| Erysipelas |
1.3% |
| Lung Disorder |
1.3% |
|
| Thrombocytopenia |
17.2% |
| Renal Failure |
8.9% |
| Pyrexia |
8.3% |
| Neutropenia |
6.5% |
| Pancreatitis Acute |
5.3% |
| Rash Maculo-papular |
5.3% |
| Weight Decreased |
5.3% |
| Toxic Epidermal Necrolysis |
4.7% |
| Toxic Skin Eruption |
4.1% |
| Henoch-schonlein Purpura |
3.6% |
| Hypotension |
3.6% |
| Renal Failure Acute |
3.6% |
| Somnolence |
3.6% |
| Vomiting |
3.6% |
| Death |
3.0% |
| Pancytopenia |
3.0% |
| Respiratory Failure |
3.0% |
| Transaminases Increased |
3.0% |
| Coma |
2.4% |
| Quadriparesis |
2.4% |
|
| Interacting |
| Drug Use For Unknown Indication |
28.4% |
| Unevaluable Event |
10.4% |
| Atrial Fibrillation |
9.0% |
| Pyrexia |
6.0% |
| Analgesic Therapy |
4.5% |
| Bone Marrow Conditioning Regimen |
4.5% |
| Essential Hypertension |
4.5% |
| Gastroenteritis |
4.5% |
| Infection Prophylaxis |
4.5% |
| Squamous Cell Carcinoma |
4.5% |
| Trigeminal Neuralgia |
4.5% |
| Infection |
3.0% |
| Bipolar Disorder |
1.5% |
| Bone Marrow Transplant |
1.5% |
| Diabetes Mellitus |
1.5% |
| Hypertension |
1.5% |
| Immunosuppression |
1.5% |
| Ischaemic Stroke |
1.5% |
| Product Used For Unknown Indication |
1.5% |
| Prophylaxis |
1.5% |
|
| Drug Interaction |
22.2% |
| Respiratory Failure |
16.7% |
| Shock |
11.1% |
| Acute Graft Versus Host Disease In Intestine |
5.6% |
| Graft Versus Host Disease |
5.6% |
| Hypoglycaemia |
5.6% |
| International Normalised Ratio Increased |
5.6% |
| Renal Failure |
5.6% |
| Renal Failure Acute |
5.6% |
| Respiratory Distress |
5.6% |
| Shock Haemorrhagic |
5.6% |
| Tremor |
5.6% |
|
